These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23963459)

  • 1. Unique substrate recognition mechanism of the botulinum neurotoxin D light chain.
    Guo J; Chen S
    J Biol Chem; 2013 Sep; 288(39):27881-7. PubMed ID: 23963459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
    Arndt JW; Chai Q; Christian T; Stevens RC
    Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of substrate recognition and specificity of botulinum neurotoxin serotype F.
    Chen S; Wan HY
    Biochem J; 2011 Jan; 433(2):277-84. PubMed ID: 21029044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of substrate recognition by the novel Botulinum Neurotoxin subtype F5.
    Guo J; Chan EW; Chen S
    Sci Rep; 2016 Jan; 6():19875. PubMed ID: 26794648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin.
    Chen S; Hall C; Barbieri JT
    J Biol Chem; 2008 Jul; 283(30):21153-9. PubMed ID: 18511417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E.
    Chen S; Barbieri JT
    J Biol Chem; 2007 Aug; 282(35):25540-7. PubMed ID: 17609207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
    Schmidt JJ; Stafford RG
    Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative characterization of botulinum neurotoxin subtypes F1 and F7 featuring differential substrate recognition and cleavage mechanisms.
    Guo J; Chan EW; Chen S
    Toxicon; 2016 Mar; 111():77-85. PubMed ID: 26748154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
    Lam KH; Sikorra S; Weisemann J; Maatsch H; Perry K; Rummel A; Binz T; Jin R
    Pathog Dis; 2018 Jun; 76(4):. PubMed ID: 29688327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition.
    Arndt JW; Yu W; Bi F; Stevens RC
    Biochemistry; 2005 Jul; 44(28):9574-80. PubMed ID: 16008342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum Neurotoxin F Subtypes Cleaving the VAMP-2 Q
    Sikorra S; Skiba M; Dorner MB; Weisemann J; Weil M; Valdezate S; Davletov B; Rummel A; Dorner BG; Binz T
    Toxins (Basel); 2018 Aug; 10(8):. PubMed ID: 30071628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique substrate recognition by botulinum neurotoxins serotypes A and E.
    Chen S; Barbieri JT
    J Biol Chem; 2006 Apr; 281(16):10906-11. PubMed ID: 16478727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F.
    Agarwal R; Schmidt JJ; Stafford RG; Swaminathan S
    Nat Struct Mol Biol; 2009 Jul; 16(7):789-94. PubMed ID: 19543288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins.
    Sikorra S; Henke T; Galli T; Binz T
    J Biol Chem; 2008 Jul; 283(30):21145-52. PubMed ID: 18511418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of a novel botulinum neurotoxin.
    Zhang S; Masuyer G; Zhang J; Shen Y; Lundin D; Henriksson L; Miyashita SI; Martínez-Carranza M; Dong M; Stenmark P
    Nat Commun; 2017 Aug; 8():14130. PubMed ID: 28770820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E.
    Hines HB; Kim AD; Stafford RG; Badie SS; Brueggeman EE; Newman DJ; Schmidt JJ
    Appl Environ Microbiol; 2008 Feb; 74(3):653-9. PubMed ID: 18083881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity.
    Jin R; Sikorra S; Stegmann CM; Pich A; Binz T; Brunger AT
    Biochemistry; 2007 Sep; 46(37):10685-93. PubMed ID: 17718519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the different catalytic activities of Clostridium neurotoxins.
    Chen S; Karalewitz AP; Barbieri JT
    Biochemistry; 2012 May; 51(18):3941-7. PubMed ID: 22510015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
    Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.
    Ahmed SA; Olson MA; Ludivico ML; Gilsdorf J; Smith LA
    Protein J; 2008 Apr; 27(3):151-62. PubMed ID: 18213512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.